- Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.
AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
2 reports, 2 independent
Updated Aug 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- AstraZeneca acquired Fusion Pharmaceuticals for approximately US$2 billion in 2024.
- Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.